Galiximab

Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors[1][2].

Product Specifications

CAS Number

[357613-77-5]

Product Name Alternative

IDEC 114; Anti-Human CD80 Recombinant Antibody

UNSPSC

12352203

Target

Apoptosis; CD28

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/galiximab.html

Purity

99.23

Solubility

10 mM in DMSO

Smiles

[Galiximab]

Molecular Weight

(145.24 kDa)

References & Citations

[1]Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) . Leuk Lymphoma. 2013 Jul;54 (7) :1405-10.|[2]Hariharan K, et al. Galiximab (anti-CD80) -induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine. Int J Oncol. 2013 Aug;43 (2) :670-6.